Last update: Dec. 18, 2013

Aminocaproic Acid

High Risk for breastfeeding


Poorly safe. Evaluate carefully.
Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives).
Read the Comment.

Anti-fibrinolytic drug used for prevention and treatment of bleeding.

On latest update no published data about breastfeeding were found

Unless patients on treatment for bleeding, since usual treatment regimens use a 8-hour-period it would be advisable to stop breastfeeding for 10-12 hours based on drug’s half-live.

Alternatives

We do not have alternatives for Aminocaproic Acid.

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Group

Aminocaproic Acid belongs to this group or family:

Tradenames

Main tradenames from several countries containing Aminocaproic Acid in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 100 %
Molecular weight 131 daltons
Protein Binding 10 %
VD 0,3 - 0,4 l/Kg
Tmax 2 hours
T1/2 2 hours

References

  1. Aminocaproico Ficha técnica 2009 Full text (in our servers)

Total visits

2,742

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana from Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM